FDA Clears Shoulder Innovations’ N-22 Humeral Head

Shoulder Innovations Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity. With the clearance, the company also officially launched the product.

Approximately 10% to 15% of the general population test positively for metal hypersensitivity and may experience persistent pain, or other symptoms associated with allergic reactions from metal implants. The N-22 Humeral Head is designed for use in anatomic total shoulder arthroplasty procedures involving patients with these complications and complements the company’s N-22 Glenosphere implant, cleared in January 2026, which is used in reverse total shoulder arthroplasty procedures involving the same patient population.

“The N-22 Humeral Head augments our line of technologies for patients with metal hypersensitivity, now providing surgeons with a metal-sensitive option across both shoulder arthroplasty configurations,” CEO of Shoulder Innovations CEO Rob Ball said. “As we continue to expand our commercial footprint across the U.S., even small incremental additions to our product line can have a meaningful impact on our relationships with surgeons and operating centers.”

Shoulder Innovations is a commercial-stage medical technology company focused on transforming the shoulder surgical care market, offering advanced implant systems for shoulder arthroplasty. These systems are a core element of the company’s ecosystem, which aims to improve the core components of shoulder surgical care—preoperative planning, implant design, and procedural efficiency—to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem also includes enabling technologies, efficient instrument systems, specialized support, and surgeon-to-surgeon collaboration. Together, these elements address longstanding clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all care sites.